Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome Vulcan Capital-led investment will enable Nautilus to bring a next-generation, single-molecule proteomics platform to market SAN CARLOS, Calif & SEATTLE, May 21, 2020-- Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76 million in an oversubscribed Series B offering that closed on Monday, May 18, 2020. Nautilus’ total funding now exceeds $100 million.